Tech Company Financing Transactions

Finch Therapeutics Funding Round

Avenir Growth Capital, Humboldt Fund and MSD Capital participated in a $90 million Series D funding round for Finch Therapeutics. The round was announced on 9/18/2020.

Transaction Overview

Company Name
Announced On
9/18/2020
Transaction Type
Venture Equity
Amount
$90,000,000
Round
Series D
Proceeds Purpose
Finch will use the proceeds from the financing to advance CP101 through the final stages of clinical development and regulatory submission in recurrent C. difficile infection (CDI), and to advance its platform and pipeline, including the initiation of Phase 1b studies evaluating FIN-211 for autism spectrum disorder (ASD) and CP101 for chronic hepatitis B (HBV).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 Inner Belt Rd. 400
Somerville, MA 02143
USA
Email Address
Overview
Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on developing and delivering innovative microbial therapies.
Profile
Finch Therapeutics LinkedIn Company Profile
Social Media
Finch Therapeutics Company Twitter Account
Company News
Finch Therapeutics News
Facebook
Finch Therapeutics on Facebook
YouTube
Finch Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Mark Smith
  Mark Smith LinkedIn Profile  Mark Smith Twitter Account  Mark Smith News  Mark Smith on Facebook
Chief Financial Officer
Gregory Perry
  Gregory Perry LinkedIn Profile  Gregory Perry Twitter Account  Gregory Perry News  Gregory Perry on Facebook
Chief Medical Officer
Zain Kassam
  Zain Kassam LinkedIn Profile  Zain Kassam Twitter Account  Zain Kassam News  Zain Kassam on Facebook
Chief Operating Officer
Andrew Noh
  Andrew Noh LinkedIn Profile  Andrew Noh Twitter Account  Andrew Noh News  Andrew Noh on Facebook
Vice President
James Burgess
  James Burgess LinkedIn Profile  James Burgess Twitter Account  James Burgess News  James Burgess on Facebook
Vice President
Irina Koroleva
  Irina Koroleva LinkedIn Profile  Irina Koroleva Twitter Account  Irina Koroleva News  Irina Koroleva on Facebook
Vice President
David Rhodes
  David Rhodes LinkedIn Profile  David Rhodes Twitter Account  David Rhodes News  David Rhodes on Facebook
Vice President
Martina Schinke
  Martina Schinke LinkedIn Profile  Martina Schinke Twitter Account  Martina Schinke News  Martina Schinke on Facebook
VP - Bus. Development
James Sigler
  James Sigler LinkedIn Profile  James Sigler Twitter Account  James Sigler News  James Sigler on Facebook
VP - General Counsel
Ben Enerson
  Ben Enerson LinkedIn Profile  Ben Enerson Twitter Account  Ben Enerson News  Ben Enerson on Facebook
VP - Operations
Anne Conway
  Anne Conway LinkedIn Profile  Anne Conway Twitter Account  Anne Conway News  Anne Conway on Facebook
VP - R & D
Sonia Timberlake
  Sonia Timberlake LinkedIn Profile  Sonia Timberlake Twitter Account  Sonia Timberlake News  Sonia Timberlake on Facebook
VP - Regulatory Affairs
Kris Piper
  Kris Piper LinkedIn Profile  Kris Piper Twitter Account  Kris Piper News  Kris Piper on Facebook
VP - Regulatory Affairs
Rozanna Yaing
  Rozanna Yaing LinkedIn Profile  Rozanna Yaing Twitter Account  Rozanna Yaing News  Rozanna Yaing on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/18/2020: Cardea Bio venture capital transaction
Next: 9/18/2020: QuickStart venture capital transaction

 

Share this article

 


About Database of VC Transactions

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary